Puerariae Lobatae Radix: botanical traits, chemical constituents, and anti-metabolic disease effects—a review

Abstract

Puerariae Lobatae Radix (PLR) is a traditional Chinese medicinal herb included in China’s inaugural list of substances recognized as both food and medicine. PLR has a long history of use and a wide range of medicinal applications. Its use is associated with a broad range of health-promoting effects. Recent studies have shown that PLR contains abundant bioactive compounds including isoflavones and polysaccharides. These findings demonstrate significant potential for the prevention and treatment of metabolic diseases (MDs). The potential mechanisms underlying these effects involve several targets and pathways, including activation of the phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) and AMPK signaling pathways; regulation of key factors, such as peroxisome proliferator-activated receptors; and modulation of the gut microbiota composition. This systematic review examines the botanical characteristics and primary chemical constituents of PLR, with particular emphasis on recent research advances, mechanisms of action, and the clinical applications of its active components in MDs intervention. This review aims to provide theoretical guidance for further development, quality improvement, and application of PLR in the prevention and treatment of MDs.

Keywords

Botanical characteristics / Chemical constituents / Clinical applications / Metabolic diseases / Puerariae Lobatae Radix

References

[1] Li D, Li Y, Yang S, et al. Diet—gut microbiota—epigenetics in metabolic diseases: from mechanisms to therapeutics. Biomed Pharmacother 2022; 153: 113290.

[2] Chen X, Zhang L, Chen W. Global, regional, and national burdens of type 1 and type 2 diabetes mellitus in adolescents from 1990 to 2021, with forecasts to 2030: a systematic analysis of the global burden of disease study 2021. BMC Med 2025; 23(1): 48.

[3] Luo J, Chen S, Wang L, et al. Pharmacological effects of polydatin in the treatment of metabolic diseases: a review. PhytoMed 2022; 102: 154161.

[4] Yin RY, Tian JX, Sun J, et al. Reconstruction of Chinese materia medica — kudzuvine root. Jilin J Tradit Chin Med 2025; 45(4): 465-467.

[5] Li L, Xu LM. Data mining analysis of prescription patterns for traditional Chinese medicines treating diabetes in the 2020 edition of the pharmacopoeia of the People’s Republic of China. Chin Med Res 2023; 36(11): 64-69.

[6] Tan YM, Hu J, Wu Q, et al. To explore the application of Pueraria category’s formulation in diabetes mellitus and its complications. J Tianjin Univ Tradit Chin Med 2021; 40(2): 183-187.

[7] Zhou X, Chai LY, Xu S, et al. Clinical evidence and traditional Chinese medicine mechanism exploration of efficacy of Pueraria Lobata Radix in improving hyperlipidemia . J Chin Med Tradit Chin Med 2025; 40(2): 654-657.

[8] Chen C, Li X, Kano Y, et al. Oriental traditional herbal medicine——puerariae flos: a systematic review. J Ethnopharmacol 2023; 306: 116089.

[9] Wong KH, Li GQ, Li KM, et al. Kudzu root: traditional uses and potential medicinal benefits in diabetes and cardiovascular diseases. J Ethnopharmacol 2011; 134(3): 584-607.

[10] Zheng G, Lin L, Zhong S, et al. Effects of puerarin on lipid accumulation and metabolism in high—fat diet—fed mice. PLoS One 2015; 10(3): e0122925.

[11] Wang D, Bu T, Li Y, et al. Pharmacological activity, pharmacokinetics, and clinical research progress of puerarin. Antioxidants 2022; 11(11): 2121.

[12] Kongkaew C, Scholfield NC, Dhippayom T, et al. Efficacy and safety of pueraria candollei var. mirifica (Airy Shaw & Suvat.) niyomdham for menopausal women: a systematic review of clinical trials and the way forward. J Ethnopharmacol 2018; 216: 162-174.

[13] Zhou X, Yu J, Wan Q, et al. Efficacy and safety of pueraria lobata radix and pueraria thomsonii radix for patients with mild dyslipidemia: a randomized, double—blind, placebo—controlled trial. J Funct Foods 2022; 98: 105284.

[14] Long ZY, Shang XH, Cao S, et al. Production areas, quality textual research and product development status of Puerariae Lobatae Radix as both medicinal and food . Mod Chin Med 2022; 24(9): 1784-1796.

[15] Liu WT. Essentials of Materia Medica . Beijing: People's Medical Publishing House; 1982.

[16] Editorial Committee of Flora of China, Chinese Academy of Sciences. Flora of China, Volume 41: Fabaceae . 1990.

[17] Xie LX. A Study on the Characteristics of Pharmacognosy of Three Varieties of Pueraria montana (Lour.) Merr. Nanchang: Jiangxi University of Chinese Medicine; 2021.

[18] Pan LL, Ren JJ, Jiang JM. Study on the regulation of dynamic accumulation of the puerarin of Pueraria lobata . Mod Chin Med 2011; 13(9): 15-17.

[19] Hou LJ, Yuan L, Feng LB, et al. High—yield cultivation techniques for kudzu root on barren hillsides and wastelands. Sichuan Agric Sci Technol 2011; 41(7): 31.

[20] Yang YP. Cultivation of Kudzu and harvesting and processing of kudzu root. Anhui Forest 2007; 53(4): 27.

[21] Gong QF. Chinese materia medica processing . Beijing: China Press of Traditional Chinese Medicine; 2012.

[22] Liu WS, Yang ZY. Effect of different processing methods on total isoflavone content in kudzu root. Chin J Mod Drug Appl 2008; 2(1): 39-41.

[23] Qiu WH, Dai H, Hu H, et al. Component comparison of Pueraria lobata (Willd.) before and after roasting . Chin Tradit Pat Med 2013; 35(10): 2213-2217.

[24] Zhong LY, Pan LL, Ma BJ, et al. Optimum simmering radix puerariae with wheat bran technology by multi—index orthogonal experiment. Chin J Inf Tradit Chin Med 2014; 21(8): 89-92.

[25] Zhang P, Fang Z, Zhao M, et al. Ethanol extract of pueraria lobata improve acute myocardial infarction in rats via regulating gut microbiota and bile acid metabolism . Phytother Res 2023; 37(12): 5932-5946.

[26] Zhu H, Xing Y, Akan OD, et al. Ultrafine comminution—assisted ultrasonic—microwave synergistic extraction of pueraria mirifica (kudzu flower and root) flavonoids. Heliyon 2023; 9(11): e21137.

[27] Kwon JE, Lim J, Kim I, et al. Isolation and identification of new bacterial stains producing equol from pueraria lobata extract fermentation. PLoS One 2018; 13(2): e0192490.

[28] Liu G, Liu Z, Yuan S. Recent advances in methods of puerarin biotransformation. Mini Rev Med Chem 2016; 16(17): 1392-1402.

[29] Niu Z, Li M, Hou X, et al. Shortening growth year improves functional features of KUDZU starch by tailoring its multi—scale structure. Int J Biol Macromol 2023; 251: 126362.

[30] Liu YM, Chen Q, Wu FF, et al. Recent advances in modern research on kudzu isoflavones. Fujian Tea. 2020; 42(1): 18-19.

[31] Zhang XN. Screening and identification of the active components from puerariae radix by HUVEC/CMC—LC—MS2. J Chromatogr B Analyt Technol Biomed Life Sci 2019; 1132(1): 121825.

[32] Zeng WS, Huang DR, Xie SW, et al. Progress in research on composition, structure, functions and mechanism of action of radix puerariae isoflavones. Food Sci 2023; 44(1): 353-361.

[33] Nakamra K, Nishihata T, Jin JS, et al. The C—glucosyl bond of puerarin was cleaved hydrolytically by a human intestinal bacterium strain PUE to yield its aglycone daidzein and an intact glucose. Chem Pharm Bull 2011; 59(1): 23-27.

[34] Jin SE, Son YK, Min BS, et al. Anti—inflammatory and antioxidant activities of constituents isolated from pueraria lobataroots. Arch Pharm Res 2012; 35(5): 823-837.

[35] Zhang J, Du W, Liu HM. Simultaneous determination of chlorogenic acid, puerarin, 3’—methoxypuerarin and arctiinin Yuandu Ganmao Granules by HPLC—DAD. Chin J Pharm Res 2020; 39(2): 88-91 + 100.

[36] Jeon J—S, Kang SW, Um B—H, et al. Preparative isolation of antioxidant flavonoids from small black soybeans by centrifugal partition chromatography and sequential solid—phase extraction. Sep Sci Technol 2014; 49(17): 2756-2764.

[37] Jung MJ, Kang SS, Jung HA, et al. Isolation of flavonoids and a cerebroside from the stem bark of Albizzia julibrissin. Arch Pharm Res 2004; 27(6): 593-599.

[38] Selepe MA, Drewes SE, Van Heerden FR. Total synthesis of the pyranoisoflavone kraussianone 1 and related isoflavones. J Nat Prod 2010; 73(10): 1680-1685.

[39] Bi D, Sun YB, Song LQ, et al. Study of chemical components from Lianhua Qingwen Capsule (I). Chin Tradit Herb Drugs 2018; 49(4): 795-800.

[40] Taoyun W, Yanli L, Xiaoran L, et al. Isoflavones from green vegetable soya beans and their antimicrobial and antioxidant activities. J Sci Food Agric 2018; 98(5): 2043-2047.

[41] Chen YC, Sugiyama Y, Abe N, et al. DPPH radical—scavenging compounds from Dou—Chi, a soybean fermented food. Biosci Biotechnol Biochem 2014; 69(5): 999-1006.

[42] Woodward MD. Phaseollin formation and metabolism in Phaseolus vulgaris. Phytochem 1980; 19(5): 921-927.

[43] Sordon S, Popłoński J, Tronina T, et al. Microbial glycosylation of daidzein, genistein and biochanin a: two new glucosides of biochanin A. Molecules 2017; 22(1): 81— 81.

[44] Ma Y, Shang Y, Zhong Z, et al. A new isoflavone glycoside from flowers of Pueraria Montana var. lobata (Willd.) Sanjappa & Pradeep. Nat Prod Res 2021; 35(9): 1459-1464.

[45] Chen H, Xu DP. Anti—inebriation components and activity of Pueraria lobata . Food Ferment Ind 2019; 45(19): 68-72.

[46] Zhang J, Chang YS, Zeng C, et al. Chemical constituents from flowers of Pueraria lobata . Chin J Exp Tradit Med Formulae 2015; 21(23): 65-67.

[47] Sun BY, He WJ, Zhang Z. Chemical constituents from Pueraria alopecuroides ratten. J Chin Med Mater 2015; 38(7): 1433-1435.

[48] Zhao Z. Studies on the Constituents of Pueraria edulis Pamp . Yunnan University of Chinese Medicine; 2017.

[49] Wang S, Shao LP, Xi Q, et al. Chemical constituents from Yupingfeng Powder. Chin Tradit Pat Med 2017; 39(2): 342-346.

[50] Cho JG, Park HJ, Huh GW, et al. Flavonoids from Pueraria mirifica roots and quantitative analysis using HPLC. Food Sci Biotechnol 2014; 23(6): 1815-1820.

[51] Wang Z—B, Chen B—B, Luo L, et al. Fractionation, physicochemical characteristics and biological activities of polysaccharides from Pueraria lobata roots. J Taiwan Inst Chem Eng 2016; 67: 54-60.

[52] Qian K. Study on Isolation, Structure Characterization and Hypoglycemic Activity of Pueraria lobata Polysaccharides . Nanchang: Jiangxi University of Chinese Medicine; 2020.

[53] Li X, Pan JX, Chen SG, et al. Research progress of chemical components and pharmacological action of Pueraria lobata . J Chin Inst Food Sci Technol 2017; 17(9): 189-195.

[54] Chen HB, Lv TX, Zhang M, et al. Two new compounds from the roots of Pueraria peduncularis and their molluscicidal effects on Pomacea canaliculata. J Asian Nat Prod Res 2018; 22(2): 144-152.

[55] Lu J, Sun JH, Tan Y, et al. New triterpenoid saponins from the flowers of Pueraria thomsonii. J Asian Nat Prod Res 2013; 15(10): 1065-1072.

[56] Zhong CQ. Studies on the Chemical Constituents from Pouzolzia zeylanica (L.) Benn. var. microphylla (Wedd.) W.T.Wang (II) . Guangzhou: Guangdong Pharmaceutical University; 2017.

[57] Shi JJ. Chemical Constituents of Pueraria lobata and P. thomsonii . Kunming: Yunnan University of Chinese Medicine; 2016.

[58] Song W, Li Y, Qiao X, et al. Chemistry of the Chinese herbal medicine puerariae radix(Ge—Gen): a review. Chin Pharm (Engl Edn) 2014; 23(6): 347.

[59] Song W, Li Y, Qiao X, et al. Chemistry of the Chinese herbal medicine puerariae radix (Ge—Gen): a review. J Chin Pharm Sci 2014; 23(6): 347.

[60] Chen R, Liu B, Wang X, et al. Effects of polysaccharide from Pueraria lobata on gut microbiota in mice. Int J Biol Macromol 2020; 158: 740-749.

[61] Zheng H. Advances of research and development of Pueraria Radices . Amino Acids Biot Resour 2006; 28(2): 24—26 + 31.

[62] Chi T, Ming D, Cunxi L. Determination of Trace Element in the Power of Radix Puerariae by Microwave Digestion—Atomic Absorption Spectroscopy. Guangdong Chemical Industry 2011; 38(5): 207-208 + 204.

[63] Zhang RT, Zhou T, Song XX, et al. Research progress on active components and pharmacological action of puerarin. Anhui Agri Sci Bull 2018; 24(1): 15-17.

[64] Wang QD, Zhao KD, Lin CQ. Study on antioxidant properties of pueraria lobata polysaccharides and its hypoglycemic effect. Sci Technol Food Ind 2022; 43(5): 381-388.

[65] Kan XY. Study on Hypolipidemic Activity and Liposomal Formulation of Pueraria lobata Polysaccharides . Zhenjiang: Jiangsu University; 2019.

[66] Chinese Diabetes Society. Chinese guidelines for the prevention and treatment of type 2 diabetes (2020 Edition) (Part II). Chin J Pract Intern Med 2021; 41(9): 757-784.

[67] Mastrototaro L, Roden M. Insulin resistance and insulin sensitizing agents. Metabolism 2021; 125: 154892.

[68] Chen X—F, Wang L, Wu Y—Z, et al. Effect of puerarin in promoting fatty acid oxidation by increasing mitochondrial oxidative capacity and biogenesis in skeletal muscle in diabetic rats. Nutr Diabetes 2018; 8(1): 1.

[69] Aguilar—Recarte D, Palomer X, Wahli W, et al. The PPARβ/δ—AMPK connection in the treatment of insulin resistance. Int J Mol Sci 2021; 22(16): 8555.

[70] Chen X, Wang L, Fan S, et al. Puerarin acts on the skeletal muscle to improve insulin sensitivity in diabetic rats involving μ—opioid receptor. Eur J Pharmacol 2018; 818: 115-123.

[71] Qian K, Tan T, Ouyang H, et al. Structural characterization of a homopolysaccharide with hypoglycemic activity from the roots of Pueraria lobata. Food Funct 2020; 11(8): 7104-7114.

[72] Luo D, Dong X, Huang J, et al. Pueraria lobata root polysaccharide alleviates glucose and lipid metabolic dysfunction in diabetic db/db mice. Pharm Biol 2021; 59(1): 380-388.

[73] Song X, Dong H, Zang Z, et al. Kudzu resistant starch: an effective regulator of type 2 diabetes mellitus. Oxid Med Cell Longevity 2021; 2021(1): 4448048.

[74] Yang L, Yao D, Yang H, et al. Puerarin protects pancreatic β—cells in obese diabetic mice via activation of GLP—1R signaling . Mol Endocrinol 2016; 30(3): 361-371.

[75] Wang C, Yao J, Ju L, et al. Puerarin ameliorates hyperglycemia in HFD diabetic mice by promoting β—cell neogenesis via GLP—1R signaling activation . PhytoMed 2020; 70: 153222.

[76] Liang T, Xu X, Ye D, et al. Caspase/AIF/apoptosis pathway: a new target of puerarin for diabetes mellitus therapy. Mol Biol Rep 2019; 46(5): 4787-4797.

[77] Srivastava S, Pandey H, Singh SK, et al. Anti—oxidant, anti—apoptotic, anti—hypoxic and anti—inflammatory conditions induced by PTY—2 against STZ—induced stress in islets. Bio Sci Trends 2019; 13(5): 382-393.

[78] Chen M. Effect and mechanism of Puerarin regulating miR—124a on mitochondrial oxidative stress injury in pancreatic β cells of type 2 diabetes mellitus . Nanning: Guangxi Medical University: 2022.

[79] Czech MP. Insulin action and resistance in obesity and type 2 diabetes. Nat Med 2017; 23(7): 804-814.

[80] Liu Y, Qiu Y, Chen Q, et al. Puerarin suppresses the hepatic gluconeogenesis via activation of PI3K/Akt signaling pathway in diabetic rats and HepG2 cells . BioMed Pharmacother 2021; 137: 111325.

[81] Qiu G, Tian W, Huan M, et al. Formononetin exhibits anti—hyperglycemic activity in alloxan—induced type 1 diabetic mice. Exp Biol Med 2017; 242(2): 223-230.

[82] Xu C, Qin N, Yan C, et al. Isolation, purification, characterization and bioactivities of a glucan from the root of Pueraria lobata. Food Funct 2018; 9(5): 2644-2652.

[83] Wang XG, Zhao X, Li Y, et al. Research progress of pathogenesis and treatment of hyperlipidemia. J Liaoning Univ TCM 2020; 22(12): 196-200.

[84] Zhu JR, Gao RL, Zhao SP, et al. Chinese guidelines for the prevention and treatment of dyslipidemia in adults (2016 revised edition). Chin Circ J 2016; 31(10): 937-953.

[85] Xu Z, Shi L, Li D, et al. Real ambient particulate matter—induced lipid metabolism disorder: Roles of peroxisome proliferators—activated receptor alpha. Ecotoxicol Environ Saf 2022; 231: 113173.

[86] Szántó M, Gupte R, Kraus WL, et al. PARPs in lipid metabolism and related diseases. Prog Lipid Res 2021; 84: 101117.

[87] Wang S, Shi X—L, Feng M, et al. Puerarin protects against CCl4—induced liver fibrosis in mice: possible role of PARP—1 inhibition. Int Immunopharmacol 2016; 38: 238-245.

[88] Ma JQ, Ding J, Zhao H, et al. Puerarin attenuates carbon tetrachloride—induced liver oxidative stress and hyperlipidaemia in mouse by JNK/c—Jun/CYP7A1 pathway. Basic Clin Pharmacol Toxicol 2014; 115(5): 389-395.

[89] Rao Y, Wen Q, Liu R, et al. PL—S2, a homogeneous polysaccharide from Radix Puerariae lobatae, attenuates hyperlipidemia via farnesoid X receptor (FXR) pathway—modulated bile acid metabolism . Int J Biol Macromol 2020; 165: 1694-1705.

[90] Zheng P, Ji G, Ma Z, et al. Therapeutic effect of puerarin on non—alcoholic rat fatty liver by improving leptin signal transduction through JAK2/STAT3 pathways. Am J Chin Med 2009; 37(1): 69-83.

[91] Choi YR, Shim J, Kim MJ. Genistin: a novel potent anti—adipogenic and anti—lipogenic agent. Molecules 2020; 25(9): 2042.

[92] Meng XW, Guo FM, Wang QQ, et al. Research progress in pharmacological effects of puerarin. Chin J Chin Mater Med 2025; 50(11): 2954-2968.

[93] Dong H, Zhao Y, Teng H, et al. Pueraria lobata antioxidant extract ameliorates non—alcoholic fatty liver by altering hepatic fat accumulation and oxidative stress. J Ethnopharmacol 2024; 333: 118468.

[94] Ding WJ, Ge JJ, Wu Y, et al. Puerarin relieves liver metabolic disorders in mice with nonalcoholic fatty liver disease. Mod Food Sci Technol 2024; 40(4): 8-17.

[95] Li Z, Cao W, Zhang Y, et al. Puerarin ameliorates non—alcoholic fatty liver disease by inhibiting lipid metabolism through FMO5. Front Pharmacol 2024; 15: 1423634.

[96] Sun C, Zhang J, Hou J, et al. Induction of autophagy via the PI3K/Akt/mTOR signaling pathway by Pueraria flavonoids improves non—alcoholic fatty liver disease in obese mice . Biomed Pharmacother 2023; 157: 114005.

[97] Engin A. The definition and prevalence of obesity and metabolic syndrome. Obes Lipotoxicity 2017; 960: 1-17.

[98] Hruby A, Hu FB. The epidemiology of obesity: a big picture. PharmacoEcon 2015; 33(7): 673-689.

[99] Huang CH, Zhang ZJ. Therapeutic potential for amyotrophic lateral sclerosis through regulating mitochondrial energy metabolism via activating AMPK/SIRT1/PGC—1α signaling pathway. Chin Pharmacol Bull 2022; 38(3): 325-329.

[100] Jung HW, Kang AN, Kang SY, et al. The root extract of Pueraria lobata and its main compound, puerarin, prevent obesity by increasing the energy metabolism in skeletal muscle. Nutrients 2017; 9(1): 33.

[101] Buhlmann E, Horváth C, Houriet J, et al. Puerariae lobatae root extracts and the regulation of brown fat activity. PhytoMed 2019; 64: 153075.

[102] Lyu QQ, Xue WZ, Liu RX, et al. A brain—to—gut signal controls intestinal fat absorption. Nature 2024; 634: 936-943.

[103] Xu D—X, Guo X—X, Zeng Z, et al. Puerarin improves hepatic glucose and lipid homeostasis in vitro and in vivo by regulating the AMPK pathway . Food Funct 2021; 12(6): 2726-2740.

[104] Lee OH, Seo DH, Park C—S, et al. Puerarin enhances adipocyte differentiation, adiponectin expression, and antioxidant response in 3T3—L1 cells. Biofactors 2010; 36(6): 459-467.

[105] Pham TH, Lee GH, Jin SW, et al. Puerarin attenuates hepatic steatosis via G—protein—coupled estrogen receptor—mediated calcium and SIRT1 signaling pathways . Phytother Res 2022; 36(9): 3601-3618.

[106] Xu X, Guo Y, Chen S, et al. The positive influence of polyphenols extracted from Pueraria lobata root on the gut microbiota and its antioxidant capability. Front Nutr 2022; 9: 868188.

[107] Zhang ZL, Xia WB, Li M, et al. Guidelines for the diagnosis and treatment of primary osteoporosis (2022). Chin J Osteoporos Bone Min Dis 2022; 15(6): 573-611.

[108] Zhong HB, Guo X, Huang LH. Puerarin stimulates osteogenesis and bone formation through ERK1/2 and p38 MAPK signaling pathways. Chin J Comp Med 2019; 29(2): 78-83.

[109] Zhou YX, Zhang H, Peng C. Puerarin: a review of pharmacological effects. Phytother Res 2014; 28(7): 961-975.

[110] Feng Q, Cheng S—Y, Yang R, et al. Puerarin promotes the viability and differentiation of MC3T3—E1 cells by enhancing LC3B—mediated autophagy through downregulation of miR—204. Exp Ther Med 2020; 19(2): 883-890.

[111] Yu DD, Zhao DY, Yang YX. Autophagy participates in puerarin—induced osteoblast differentiation. J China Med Univ 2021; 50(9): 779-784.

[112] Zhao X, Zhou J, Liu Y, et al. Puerarin alleviates osteoporosis in rats by targeting the JAK2/STAT3 signaling pathway. Biomolecules BioMed 2024; 24(6): 1651-1661.

[113] Zhao CH, Li SC, Li PH, et al. Research progress of signal molecules regulating osteoclast function. Chin J Osteoporos 2021; 27(9): 1361-1365.

[114] Park KH, Gu DR, Jin SH, et al. Pueraria lobate inhibits RANKL—mediated osteoclastogenesis via downregulation of CREB/PGC1β/c—Fos/NFATc1 signaling . Am J Chin Med 2017; 45(8): 1725-1744.

[115] Feng Y, Tang X. FoxO1 as the critical target of puerarin to inhibit osteoclastogenesis and bone resorption (Mar 30, 10.1093/jpp/rgae033, 2024). J Pharm Pharmacol 2024; 76(9): 813-823.

[116] Hu X, Wang Z, Wang W, et al. Irisin as an agent for protecting against osteoporosis: a review of the current mechanisms and pathways. J Adv Res 2024; 62: 175-186.

[117] Yang D, Guan ZY. Intervention effects of puerarin on ovariectomized osteoporotic rats via the PPAR—γ/Axin2/Wnt signaling pathway . Chin J Gerontol 2023; 43(13): 3228-3232.

[118] Lee MR, Kim B, Lee Y, et al. Ameliorative effects of pueraria lobata extract on postmenopausal symptoms through promoting estrogenic activity and bone markers in ovariectomized rats. Evid Based Complement Alternat Med 2021: 7924400.

[119] Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol 2020; 16(7): 380-390.

[120] Zhang Y, Zhong XM, Yang J, et al. Effect of puerarin on the expression of inflammatory cytokines in gouty arthritis mice. Immunol J 2020; 36(10): 903-907 + 913.

[121] Wang Y. Effects of myricetin and puerarin on hyperuricemia and their significance. Inner Mongol J Tradit Chin Med 2010; 29(19): 9-10.

[122] Shen QR. The Screening and Study on the Inhibition Kinetics of Xanthine Oxidase Inhibitors from Chinese Herbal Medicine . Nanchang: Nanchang University; 2015.

[123] Shi S, Zhang RT, Shang XY, et al. Effect of puerarin on serum uric acid in hyperuricemic rats. Food Sci Technol 2014; 39(2): 216-220.

[124] Zhang HC, Zhang Y, Lü GF, et al. The puerarin impact on the expression of ABCG2 in human renal proximal tubule epithelial cells. SH J TCM Mar 2016; 50(3): 74-77.

[125] Meng XW, Wang QQ, Zhang N, et al. Anti—inflammatory mechanisms of flavonoids in pueraria lobata: immune cell regulation and molecular mechanisms. J Funct Foods 2025; 131: 106954.

[126] Xiong YC, Wu HF, Zhang ET, et al. EEffect of puerarin on expression of TLR4/NK—κB pathway of acute gouty arthritis rats. Chin J Mod Med. 2020; 30(7): 14-18.

[127] Zhang Y, Zhong XM, Yang J, et al. Effect of puerarin on the expression of inflammatory cytokines in gouty arthritis mice. Immunol J 2020; 36(10): 903-907 + 913.

[128] Wang W, Lu B, Gu P, et al. From new frontiers to new paradigms:state of the art for gut microbiome in metabolic disease. J Nephrol Dial Transplant 2025; 34(5): 453-457.

[129] Zhu HY, Liu Y, Li JR, et al. Effect and mechanism of Puerariae Lobatae Radix in alleviating insulin resistance in T2DM db/db mice based on intestinal flora. Chin J Chin. Mater Med 2023; 48(17): 4693-4701.

[130] Sochacka K, Kotowska A, Lachowicz—Wisniewska S. The role of gut microbiota, nutrition, and physical activity in depression and obesity—interdependent mechanisms/co—occurrence. Nutrients 2024; 16(7): 1039.

[131] Sun CB. The Mechanism of Pueraria Regulating Hyperlipidemia Based on Intestinal Bacteria Metabolism . Kunming: Yunnan University of Chinese Medicine; 2021.

[132] Fang J, Yu C—H, Li X—J, et al. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications. Front Cell Infect Microbiol 2022; 12: 997018.

[133] Li Q, Liu W, Zhang H, et al. α—D—1, 3—glucan from radix puerariae thomsonii improves NAFLD by regulating the intestinal flora and metabolites. Carbohydr Polym 2023; 299: 120197.

[134] Wang L, Wu Y, Zhuang L, et al. Puerarin prevents high—fat diet—induced obesity by enriching Akkermansia muciniphila in the gut microbiota of mice. PLoS One 2019; 14(6): e0218490.

[135] Everard A, Belzer C, Geurts L, et al. Cross—talk between Akkermansia muciniphila and intestinal epithelium controls diet—induced obesity. Proc Natl Acad Sci USA 2013; 110(22): 9066-9071.

[136] Britton RA, Irwin R, Quach D, et al. Probiotic L. reuteri treatment prevents bone loss in a menopausal ovariectomized mouse model. J Cell Physiol 2014; 229(11): 1822-1830.

[137] Sjögren K, Engdahl C, Henning P, et al. The gut microbiota regulates bone mass in mice. J Bone Min Res 2012; 27(6): 1357-1367.

[138] Li B, Liu M, Wang Y, et al. Puerarin improves the bone micro—environment to inhibit OVX—induced osteoporosis via modulating SCFAs released by the gut microbiota and repairing intestinal mucosal integrity . Biomed Pharmacotherapy 2020; 132: 110923.

[139] Zhong WQ, Wu ML, Guo MJ. Clinical effect of Pueraria lobata extract on senile osteoporotic fracture. Inner Mongol J Tradit Chin Med 2020; 39(6): 1-2.

[140] Wang L, Cheng H. Exploration of treated with Gegen Qinlian decoction prescription on type 2 diabetic rats based on metabolomics. Glob Tradit Chin Med 2019; 12(1): 19-23.

[141] Gong J. Clinical observation of Gegen Qinlian decoction combined with saxagliptin in the treatment of type 2 diabetes mellitus. J Pract Chin Med 2019; 35(4): 481-482.

[142] Zhao ZQ. Clinical Observation on the Treatment of Hyperlipidemia with Gegen Qinlian Granules (Dampness—Heat Type) . Changchun: Changchun University of Chinese Medicine, 2021.

[143] Tian T, Jin LJ, Shen HR, et al. Effect of Huangqi Gegen decoction combined with metformin on insulin resistance in patients with type 2 diabetes. Clin J Tradit Chin Med 2019; 31(2): 304-306.

[144] Tang BS. Effect of Huangqi Gegen decoction on insulin resistance and adiponectin for elderly patients with type 2diabetes mellitus. J Sichuan Tradit Chin Med 2021; 39(2): 120-123.

[145] He G, Ma Y, Liu H, et al. Clinical study of puerarin combined with α—lipoic acid in the treatment of diabetes mellitus with carotid atherosclerosis. China Med Herald 2020; 17(10): 82-85.

[146] Zhang YQ, Zhang LM. Effects of puerarin treatment on hemodynamics and blood rheology in diabetic retinopathy patients. Int Eye Sci 2013; 13(10): 2057-2059.

[147] Yin CM, Guo JJ, Liu YL, et al. Observation of therapentic effect of astragalus and puerarine injection on patients with type II diabetes Mellitus. J Basic Chin Med 2001; 7(1): 57-59.

[148] Bao YS, Deng CC, Chen X. Clinical observation of astragalus injection combined with puerarin injection in the treatment of type 2 diabetes. Clin J Tradit Chin Med 2007; 19(4): 369-370.

[149] Wang JX, Wu WP. Curative effect observation of puerarin and epalrestat in the treatment of diabetic peripheral neuropathy. Chin Commun Phys 2016; 32(21): 44-45.

[150] Wang ST. Clinical analysis of Gegen Qinlian decoction in the treatment of patients with diabetes mellitus. New World Diab 2025; 28(5): 56-59.

[151] He GX, Ma YH, Liu HY, et al. Clinical study of puerarin combined with α—lipoic acid in the treatment of diabetes mellitus with carotid atherosclerosis. Chin Med Herald 2020; 17(10): 82-85.